|
|
| Line 1: |
Line 1: |
| == '''What is Eylea?''' ==
| | #REDIRECT [[Aflibercept]] |
|
| |
|
| * '''Eylea''' ([[Aflibercept]]) is '''a vascular endothelial growth factor (VEGF) inhibitor''' used for the treatment of wet age-related [[macular degeneration]].
| | {{R from trade name}} |
| * It is also used to treat [[macular edema]] after [[retinal vein occlusion]], [[diabetic macular edema]], and [[diabetic retinopathy]].
| |
| | |
| [[File:Aflibercept (Eylea®).svg|thumb|Aflibercept (Eylea®)]]
| |
| | |
| <youtube>
| |
| title='''{{PAGENAME}}'''
| |
| movie_url=http://www.youtube.com/v/v=_lgySn0brjw
| |
| embed_source_url=http://www.youtube.com/v/v=_lgySn0brjw
| |
| &rel=1
| |
| wrap = yes
| |
| width=750
| |
| height=600
| |
| </youtube>
| |
| | |
| | |
| == '''What are the uses of this medicine?''' ==
| |
| | |
| Eylea (Aflibercept) used for the treatment of:
| |
| * Neovascular (Wet) [[Age-Related Macular Degeneration]] (AMD)
| |
| * [[Macular Edema]] Following [[Retinal Vein Occlusion]] (RVO)
| |
| * [[Diabetic macular edema|Diabetic Macular Edema]] (DME)
| |
| * [[Diabetic Retinopathy]] (DR)
| |
| | |
| | |
| == '''How does this medicine work?''' ==
| |
| | |
| <youtube>
| |
| title='''{{PAGENAME}}'''
| |
| movie_url=http://www.youtube.com/v=XrqkEE4D_m8
| |
| embed_source_url=http://www.youtube.com/v=XrqkEE4D_m8
| |
| &rel=1
| |
| wrap = yes
| |
| width=750
| |
| height=600
| |
| </youtube>
| |
| | |
| * Aflibercept acts as '''a soluble decoy receptor that binds VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors'''.
| |
| * Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells.
| |
| * VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells.
| |
| * PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes.
| |
| * Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability.
| |
| | |
| | |
| == '''Who Should Not Use this medicine ?''' ==
| |
| | |
| This medicine cannot be used in patients with:
| |
| * ocular or periocular infections
| |
| * active intraocular [[inflammation]]
| |
| * known [[hypersensitivity]] to aflibercept or any of the excipients in Eylea
| |
| | |
| | |
| == '''What drug interactions can this medicine cause?''' ==
| |
| | |
| * Tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
| |
| | |
| | |
| == '''Is this medicine FDA approved?''' ==
| |
| | |
| * In November 2011, the United States Food and Drug Administration (FDA) approved aflibercept for the treatment of [[wet macular degeneration]].
| |
| | |
| | |
| == '''How should this medicine be used?''' ==
| |
| | |
| '''Recommended dosage:'''
| |
| '''Neovascular (Wet) Age-Related Macular Degeneration (AMD):'''
| |
| * The recommended dose for Eylea is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).
| |
| | |
| '''Macular Edema Following Retinal Vein Occlusion (RVO):'''
| |
| * The recommended dose for Eylea is 2 mg (0.05 mL) administered by intravitreal injection once every 4 weeks (approximately every 25 days, monthly).
| |
| | |
| '''Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR):'''
| |
| * The recommended dose for Eylea is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).
| |
|
| |
| '''Administration:'''
| |
| * Aflibercept injection comes as a solution (liquid) to be injected into the eye by a doctor.
| |
| * It is usually given in a doctor's office.
| |
| * Your doctor will give you injections on a schedule that is best for you and your condition.
| |
| * Before you receive an aflibercept injection, your doctor will clean your eye to prevent infection and numb your eye to reduce discomfort during the injection.
| |
|
| |
| | |
| == '''What are the dosage forms and brand names of this medicine?''' ==
| |
| | |
| This medicine is available in fallowing doasage form:
| |
| * As Injection: 2 mg/0.05 mL solution in a single-dose pre-filled syringe
| |
| * Injection: 2 mg/0.05 mL solution in a single-dose vial
| |
| | |
| This medicine is available in fallowing brand namesː
| |
| * '''Eylea'''
| |
| | |
| | |
| =='''What side effects can this medication cause?'''==
| |
| | |
| The most common side effects of this medicine include:
| |
| * conjunctival [[hemorrhage]]
| |
| * eye pain
| |
| * [[cataract]]
| |
| * [[Vitreous Detachment|vitreous detachment]]
| |
| * [[vitreous floaters]]
| |
| * [[intraocular pressure]] increased
| |
| | |
| Eylea can cause the following serious side effects:
| |
| * eye redness or pain
| |
| * eye sensitivity to light
| |
| * decrease or changes in vision
| |
| * bleeding in or around the eye
| |
| * seeing ''floaters'' or small specks
| |
| * injection site pain
| |
| * seeing flashes of lights
| |
| * [[dizziness]] or faintness
| |
| * weakness or numbness of an arm or leg
| |
| * [[rash]]
| |
| * itching
| |
| * [[hives]]
| |
| * difficulty breathing or swallowing
| |
| * [[chest pain]]
| |
| * shortness of breath
| |
| * sweating
| |
| * slow or difficult speech
| |
| | |
| | |
| ==''' What special precautions should I follow?''' ==
| |
| | |
| * [[Endophthalmitis]] and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
| |
| * Increases in [[intraocular pressure]] have been seen within 60 minutes of an intravitreal injection. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
| |
| * There is a potential risk of [[Arterial thromboembolism|arterial thromboembolic events]] following intravitreal use of VEGF inhibitors, including Eylea. There were no reported thromboembolic events in the patients treated with Eylea in the first six months of the RVO studies.
| |
|
| |
| | |
| == '''What to do in case of emergency/overdose?''' ==
| |
| | |
| * {{overdose}}
| |
| | |
| | |
| == '''Can this medicine be used in pregnancy?''' ==
| |
| | |
| * Adequate and well-controlled studies with Eylea have not been conducted in pregnant women.
| |
| * Eylea can cause fetal harm when administered to a pregnant woman.
| |
| * Eylea should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| | |
| | |
| =='''Can this medicine be used in children?'''==
| |
| | |
| * The safety and effectiveness of Eylea in pediatric patients have not been established.
| |
| | |
| | |
| == '''What are the active and inactive ingredients in this medicine?''' ==
| |
| | |
| '''Active Ingredient:'''
| |
| * aflibercept
| |
| | |
| '''Inactive Ingredients:'''
| |
| * sodium phosphate
| |
| * sodium chloride
| |
| * polysorbate 20
| |
| * sucrose
| |
| | |
| | |
| == '''Who manufactures and distributes this medicine?''' ==
| |
| | |
| '''Manufactured by:'''
| |
| * [[Regeneron Pharmaceuticals Inc|Regeneron Pharmaceuticals, Inc.]]
| |
| * 777 Old Saw Mill River Road
| |
| * Tarrytown, NY
| |
| | |
| * Eylea is a registered trademark of Regeneron Pharmaceuticals, Inc.
| |
| | |
| | |
| == '''What should I know about storage and disposal of this medication?''' ==
| |
| | |
| * Refrigerate Eylea at 2°C to 8ºC (36°F to 46ºF).
| |
| * Do not freeze.
| |
| * Do not use beyond the date stamped on the carton and container label.
| |
| * Store in the original carton until time of use to protect from light.
| |
| * Do not open sealed blister tray until time of use.
| |
| | |
| | |
| {{coststubd}}
| |
| {{Extracellular chemotherapeutic agents}}
| |
| {{Immunosuppressants}}
| |
| {{Ocular vascular disorder agents}}
| |
| {{Portal bar | Medicine}}
| |
| | |
| [[Category:Angiogenesis inhibitors]]
| |
| [[Category:Bayer brands]]
| |
| [[Category:Breakthrough therapy]]
| |
| [[Category:Engineered proteins]]
| |
| [[Category:Ophthalmology drugs]]
| |
| [[Category:Sanofi]]
| |
